Bortezomib

Generic Name
Bortezomib
Brand Names
Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
Drug Type
Small Molecule
Chemical Formula
C19H25BN4O4
CAS Number
179324-69-7
Unique Ingredient Identifier
69G8BD63PP
Background

Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.

Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.

Indication

Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions
Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
Associated Therapies
-
Clinical Trials
Related News

Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors

First Posted Date
2008-02-25
Last Posted Date
2017-12-02
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
37
Registration Number
NCT00622674
Locations
🇺🇸

Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors

First Posted Date
2008-02-21
Last Posted Date
2017-11-29
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
17
Registration Number
NCT00620295
Locations
🇺🇸

Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens

First Posted Date
2008-02-08
Last Posted Date
2009-07-14
Lead Sponsor
Millennium Pharmaceuticals, Inc.
Target Recruit Count
91
Registration Number
NCT00610792
Locations
🇨🇭

Kantonsspital St. Gallen, St. Gallen, CH, Switzerland

🇨🇭

Gynecologic Oncology Unit, Ospedale Sant' Anna, Turin, Switzerland

🇮🇹

Istituto Nazionale dei Tumori, Milan, Italy

and more 4 locations

Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma

Phase 2
Completed
Conditions
Glioblastoma
Gliosarcoma
Interventions
Drug: Avastin
Drug: Bortezomib
First Posted Date
2008-02-08
Last Posted Date
2014-03-12
Lead Sponsor
Duke University
Target Recruit Count
56
Registration Number
NCT00611325
Locations
🇺🇸

Duke University Health System, Durham, North Carolina, United States

Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

First Posted Date
2008-02-06
Last Posted Date
2011-05-17
Lead Sponsor
Mayo Clinic
Target Recruit Count
63
Registration Number
NCT00609167
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇨🇦

Princess Margaret Hospital, Toronto, Ontario, Canada

An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)

First Posted Date
2008-02-06
Last Posted Date
2012-01-30
Lead Sponsor
Millennium Pharmaceuticals, Inc.
Target Recruit Count
61
Registration Number
NCT00608907
Locations
🇮🇱

Hematology Institute - Davidoff Center - Rabin Medical Center, Petach Tikva, Israel

🇵🇱

Medical Academy - Dept of Hematology and Transplantology, Gdansk, Poland

🇬🇧

Hematology Department Combined Laboratories - Derriford Hospital, Plymouth, United Kingdom

and more 6 locations

Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma

Phase 3
Completed
Conditions
Multiple Myeloma
Interventions
Drug: Thalidomide
Drug: Bortezomib
First Posted Date
2008-01-28
Last Posted Date
2011-02-09
Lead Sponsor
Nordic Myeloma Study Group
Target Recruit Count
300
Registration Number
NCT00602511
Locations
🇳🇴

Trondheim University Hospital, Trondheim, Norway

🇩🇰

Herlev University Hospital, Herlev, Denmark

🇩🇰

Odense University Hospital, Odense, Denmark

and more 24 locations

Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

First Posted Date
2008-01-18
Last Posted Date
2020-08-10
Lead Sponsor
AIDS Malignancy Consortium
Target Recruit Count
23
Registration Number
NCT00598169
Locations
🇺🇸

Emory Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

Baylor College of Medicine, Houston, Texas, United States

🇺🇸

UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States

and more 14 locations

Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma

First Posted Date
2007-12-28
Last Posted Date
2019-12-17
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
30
Registration Number
NCT00581776
Locations
🇺🇸

University Of Wisconsin Cancer Center, Madison, Wisconsin, United States

A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia

Phase 1
Completed
Conditions
Myelodysplasia
Interventions
Drug: Bortezomib
Drug: Lenalidomide
First Posted Date
2007-12-24
Last Posted Date
2012-03-08
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
23
Registration Number
NCT00580242
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy